CTOs on the Move

Aro Biotherapeutics

www.arobiotx.com

 
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.arobiotx.com
  • 3675 Market Street Suite 200
    Philadelphia, PA USA 19104
  • Phone: n/a

Executives

Name Title Contact Details
Sukumar Sakamuri
 Chief Technology Officer Profile

Funding

Aro Biotherapeutics raised $13M on 12/11/2018
Aro Biotherapeutics raised $48M on 12/21/2020

Similar Companies

Bio Focus DPI

Bio Focus DPI is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Dental

Family Dental is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMMY

Manufacturer of diagnostics for global fungal diseases such as, cryptococcosis, aspergillosis, histoplasmosis, coccidioidomycosis (Valley Fever), blastomycosis, and candida.

Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.

Checkerspot

Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.